Detalhe da pesquisa
1.
Simvastatin in Critically Ill Patients with Covid-19.
N Engl J Med
; 389(25): 2341-2354, 2023 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888913
2.
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
N Engl J Med
; 385(9): 777-789, 2021 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351722
3.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
N Engl J Med
; 385(9): 790-802, 2021 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351721
4.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
JAMA
; 329(1): 39-51, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525245
5.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
JAMA
; 329(14): 1183-1196, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37039790
6.
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
JAMA
; 330(18): 1745-1759, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877585
7.
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1247-1259, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35315874
8.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 326(17): 1690-1702, 2021 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606578
9.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
JAMA
; 324(13): 1317-1329, 2020 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32876697
10.
Adaptive Randomization of Neratinib in Early Breast Cancer.
N Engl J Med
; 375(1): 11-22, 2016 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27406346
11.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
N Engl J Med
; 375(1): 23-34, 2016 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27406347
12.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Clin Cancer Res
; 30(4): 729-740, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109213
13.
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
Breast Cancer Res Treat
; 132(3): 871-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21796368
14.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Breast Cancer Res Treat
; 132(3): 1049-62, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22198468
15.
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
NPJ Breast Cancer
; 8(1): 128, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36456573
16.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
JAMA
; 305(18): 1873-81, 2011 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21558518
17.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Intensive Care Med
; 47(8): 867-886, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251506
18.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
; 7(1): 131, 2021 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611148
19.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Nat Commun
; 12(1): 6428, 2021 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34741023
20.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J Clin Oncol
; 38(10): 1059-1069, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32031889